Clinical trials: Huntington's Dementia
Huntington's Disease, Chorea
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
- Trial name
- NCT01019473
- Testing
- AFQ056
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials…
- Trial name
- NCT00212316
- Testing
- sodium phenylbutyrate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Huntington Disease
Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression
Intro Huntington's disease (HD) patients suffer from motor, cognitive and behavioral impairments, with heterogeneous phenotypes and variable time course.
- Trial name
- I2BIO-HD (NCT05808153)
- Testing
- radiotracer injection
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease
Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene. Several pathophysiological mechanisms have been evoked, including an alteration of the signaling…
- Trial name
- LCR-MH (NCT04012411)
- Testing
- Brain MRI, Lumbar Punction, Blood sample
- Where
- France
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Huntington's Disease
Efficacy and Safety of Tetrabenazine in Chorea
The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo
- Trial name
- NCT00219804
- Sponsor
- Prestwick Pharmaceuticals
Huntington Disease
Pilot Study of Minocycline in Huntington's Disease
This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD.
- Trial name
- NCT00277355
- Testing
- minocycline
- Where
- 12 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Merit Cudkowicz
Apathy, Huntington's Disease
Apathy Cure Through Bupropion in Huntington's Disease
The influence of bupropion compared to placebo on the change of apathy as quantified by the apathy evaluation scale (AES-I, where I [informant] is a friend or family member familiar with the daily activities of the subject) in…
- Trial name
- Action-HD (NCT01914965)
- Testing
- Bupropion
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Huntington Disease
Benchmarking Integrated Care for People Living With Huntington's Disease in England
The survey and full study information can be accessed here: https://southampton.qualtrics.com/jfe/form/SV_8iEedDJZy4xaiI6 The goal of this anonymous survey is to benchmark integrated care from the perspective of service users in…
- Trial name
- Integrate-HD (NCT05828992)
- Testing
- No intervention administered
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Huntington's Disease
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
- Trial name
- NCT05107128
- Testing
- SAGE-718
- Where
- 49 sites in United States, Australia and 2 more
- Volunteers
- 189 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington Disease
Study of Biomarkers That Predict the Evolution of Huntington's Disease
Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder typically becoming noticeable in middle age.
- Trial name
- BIOHD (NCT01412125)
- Testing
- Huntington patient evaluation, Healthy subject evaluation
- Where
- France
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Damage, Chronic
The Effect of tDCS on Subcortical Brain Functioning
This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve certain abilities related to cognition, emotion and/or physical functioning in individuals with subcortical brain damage.
- Trial name
- NCT01602276
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Huntington Disease
Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
- Trial name
- NCT00675077
- Testing
- Far Infrared Radiation
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- GAAD Medical Research Institute Inc.
Huntington's Disease
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's disease.
- Trial name
- MermaiHD (NCT00665223)
- Testing
- ACR16
- Where
- 31 sites in Austria, Belgium and 6 more
- Volunteers
- 437 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntington's Disease
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
- Trial name
- NCT06585449
- Testing
- ALN-HTT02
- Where
- 19 sites in Canada, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Alnylam Pharmaceuticals
Huntington Disease
TEsting METformin Against Cognitive Decline in HD
Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease.
- Trial name
- TEMET (NCT04826692)
- Testing
- Metformin
- Where
- 9 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Juvenile Huntington Disease, Juvenile-Onset Huntington Disease
Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease
The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: Is brain development different in JoHD than Adult-onset…
- Trial name
- NCT05707663
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Iowa
Huntington Disease
Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease
The objective of the study is to validate the use of wearable sensors and digital health technologies for monitoring disease activity in Huntington's Disease (HD).
- Trial name
- BioDigit HD-02 (NCT07315984)
- Where
- 2 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BioSensics
Huntington Disease
Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD
Huntington's disease is a rare and fatal monogenic neurodegenerative disorder whose molecular origin is an expansion of CAG triplets within the first exon of the Huntingtin gene.
- Trial name
- FibroTG-HD (NCT06444217)
- Testing
- skin biopsy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Angers
Huntington Disease
A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
In the study the investigators plan to include 100 early affected HD patients (5 ≤ UHDRS ≤ 40) in a randomized, double-blind, controlled study in 2 centers (France and the Netherlands).
- Trial name
- TRIHEP3 (NCT02453061)
- Testing
- Triheptanoin oil
- Where
- 2 sites in France, Netherlands
- Volunteers
- 100 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France